Copyright Reports & Markets. All rights reserved.

Global and China Drugs for Solid Tumors Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Drugs for Solid Tumors Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Small Molecules
    • 1.2.3 Biologics
  • 1.3 Market by Application
    • 1.3.1 Global Drugs for Solid Tumors Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Academic and Research Institutes
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Drugs for Solid Tumors Market Perspective (2015-2026)
  • 2.2 Global Drugs for Solid Tumors Growth Trends by Regions
    • 2.2.1 Drugs for Solid Tumors Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Drugs for Solid Tumors Historic Market Share by Regions (2015-2020)
    • 2.2.3 Drugs for Solid Tumors Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Drugs for Solid Tumors Players by Market Size
    • 3.1.1 Global Top Drugs for Solid Tumors Players by Revenue (2015-2020)
    • 3.1.2 Global Drugs for Solid Tumors Revenue Market Share by Players (2015-2020)
  • 3.2 Global Drugs for Solid Tumors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Drugs for Solid Tumors Revenue
  • 3.4 Global Drugs for Solid Tumors Market Concentration Ratio
    • 3.4.1 Global Drugs for Solid Tumors Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Drugs for Solid Tumors Revenue in 2019
  • 3.5 Key Players Drugs for Solid Tumors Area Served
  • 3.6 Key Players Drugs for Solid Tumors Product Solution and Service
  • 3.7 Date of Enter into Drugs for Solid Tumors Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Drugs for Solid Tumors Breakdown Data by Type (2015-2026)

  • 4.1 Global Drugs for Solid Tumors Historic Market Size by Type (2015-2020)
  • 4.2 Global Drugs for Solid Tumors Forecasted Market Size by Type (2021-2026)

5 Drugs for Solid Tumors Breakdown Data by Application (2015-2026)

  • 5.1 Global Drugs for Solid Tumors Historic Market Size by Application (2015-2020)
  • 5.2 Global Drugs for Solid Tumors Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Drugs for Solid Tumors Market Size (2015-2026)
  • 6.2 North America Drugs for Solid Tumors Market Size by Type (2015-2020)
  • 6.3 North America Drugs for Solid Tumors Market Size by Application (2015-2020)
  • 6.4 North America Drugs for Solid Tumors Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Drugs for Solid Tumors Market Size (2015-2026)
  • 7.2 Europe Drugs for Solid Tumors Market Size by Type (2015-2020)
  • 7.3 Europe Drugs for Solid Tumors Market Size by Application (2015-2020)
  • 7.4 Europe Drugs for Solid Tumors Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Drugs for Solid Tumors Market Size (2015-2026)
  • 8.2 China Drugs for Solid Tumors Market Size by Type (2015-2020)
  • 8.3 China Drugs for Solid Tumors Market Size by Application (2015-2020)
  • 8.4 China Drugs for Solid Tumors Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Drugs for Solid Tumors Market Size (2015-2026)
  • 9.2 Japan Drugs for Solid Tumors Market Size by Type (2015-2020)
  • 9.3 Japan Drugs for Solid Tumors Market Size by Application (2015-2020)
  • 9.4 Japan Drugs for Solid Tumors Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Drugs for Solid Tumors Market Size (2015-2026)
  • 10.2 Southeast Asia Drugs for Solid Tumors Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Drugs for Solid Tumors Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Drugs for Solid Tumors Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Hoffmann-La Roche
    • 11.1.1 Hoffmann-La Roche Company Details
    • 11.1.2 Hoffmann-La Roche Business Overview
    • 11.1.3 Hoffmann-La Roche Drugs for Solid Tumors Introduction
    • 11.1.4 Hoffmann-La Roche Revenue in Drugs for Solid Tumors Business (2015-2020))
    • 11.1.5 Hoffmann-La Roche Recent Development
  • 11.2 Novartis
    • 11.2.1 Novartis Company Details
    • 11.2.2 Novartis Business Overview
    • 11.2.3 Novartis Drugs for Solid Tumors Introduction
    • 11.2.4 Novartis Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.2.5 Novartis Recent Development
  • 11.3 Celgene
    • 11.3.1 Celgene Company Details
    • 11.3.2 Celgene Business Overview
    • 11.3.3 Celgene Drugs for Solid Tumors Introduction
    • 11.3.4 Celgene Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.3.5 Celgene Recent Development
  • 11.4 Johnson & Johnson
    • 11.4.1 Johnson & Johnson Company Details
    • 11.4.2 Johnson & Johnson Business Overview
    • 11.4.3 Johnson & Johnson Drugs for Solid Tumors Introduction
    • 11.4.4 Johnson & Johnson Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.4.5 Johnson & Johnson Recent Development
  • 11.5 Pfizer
    • 11.5.1 Pfizer Company Details
    • 11.5.2 Pfizer Business Overview
    • 11.5.3 Pfizer Drugs for Solid Tumors Introduction
    • 11.5.4 Pfizer Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.5.5 Pfizer Recent Development
  • 11.6 BMS
    • 11.6.1 BMS Company Details
    • 11.6.2 BMS Business Overview
    • 11.6.3 BMS Drugs for Solid Tumors Introduction
    • 11.6.4 BMS Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.6.5 BMS Recent Development
  • 11.7 Eli Lilly
    • 11.7.1 Eli Lilly Company Details
    • 11.7.2 Eli Lilly Business Overview
    • 11.7.3 Eli Lilly Drugs for Solid Tumors Introduction
    • 11.7.4 Eli Lilly Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.7.5 Eli Lilly Recent Development
  • 11.8 GSK
    • 11.8.1 GSK Company Details
    • 11.8.2 GSK Business Overview
    • 11.8.3 GSK Drugs for Solid Tumors Introduction
    • 11.8.4 GSK Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.8.5 GSK Recent Development
  • 11.9 Merck
    • 11.9.1 Merck Company Details
    • 11.9.2 Merck Business Overview
    • 11.9.3 Merck Drugs for Solid Tumors Introduction
    • 11.9.4 Merck Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.9.5 Merck Recent Development
  • 11.10 Sanofi
    • 11.10.1 Sanofi Company Details
    • 11.10.2 Sanofi Business Overview
    • 11.10.3 Sanofi Drugs for Solid Tumors Introduction
    • 11.10.4 Sanofi Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 11.10.5 Sanofi Recent Development
  • 11.11 AbbVie
    • 10.11.1 AbbVie Company Details
    • 10.11.2 AbbVie Business Overview
    • 10.11.3 AbbVie Drugs for Solid Tumors Introduction
    • 10.11.4 AbbVie Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.11.5 AbbVie Recent Development
  • 11.12 AstraZeneca
    • 10.12.1 AstraZeneca Company Details
    • 10.12.2 AstraZeneca Business Overview
    • 10.12.3 AstraZeneca Drugs for Solid Tumors Introduction
    • 10.12.4 AstraZeneca Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.12.5 AstraZeneca Recent Development
  • 11.13 Bayer
    • 10.13.1 Bayer Company Details
    • 10.13.2 Bayer Business Overview
    • 10.13.3 Bayer Drugs for Solid Tumors Introduction
    • 10.13.4 Bayer Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.13.5 Bayer Recent Development
  • 11.14 Biogen
    • 10.14.1 Biogen Company Details
    • 10.14.2 Biogen Business Overview
    • 10.14.3 Biogen Drugs for Solid Tumors Introduction
    • 10.14.4 Biogen Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.14.5 Biogen Recent Development
  • 11.15 Boehringer Ingelheim
    • 10.15.1 Boehringer Ingelheim Company Details
    • 10.15.2 Boehringer Ingelheim Business Overview
    • 10.15.3 Boehringer Ingelheim Drugs for Solid Tumors Introduction
    • 10.15.4 Boehringer Ingelheim Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.15.5 Boehringer Ingelheim Recent Development
  • 11.16 Boston Biomedical
    • 10.16.1 Boston Biomedical Company Details
    • 10.16.2 Boston Biomedical Business Overview
    • 10.16.3 Boston Biomedical Drugs for Solid Tumors Introduction
    • 10.16.4 Boston Biomedical Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.16.5 Boston Biomedical Recent Development
  • 11.17 Daiichi Sankyo
    • 10.17.1 Daiichi Sankyo Company Details
    • 10.17.2 Daiichi Sankyo Business Overview
    • 10.17.3 Daiichi Sankyo Drugs for Solid Tumors Introduction
    • 10.17.4 Daiichi Sankyo Revenue in Drugs for Solid Tumors Business (2015-2020)
    • 10.17.5 Daiichi Sankyo Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Drugs for Solid Tumors Scope and Market Size
    Drugs for Solid Tumors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Solid Tumors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Small Molecules
    Biologics

    Market segment by Application, split into
    Hospitals
    Clinics
    Academic and Research Institutes

    Based on regional and country-level analysis, the Drugs for Solid Tumors market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Drugs for Solid Tumors market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Hoffmann-La Roche
    Novartis
    Celgene
    Johnson & Johnson
    Pfizer
    BMS
    Eli Lilly
    GSK
    Merck
    Sanofi
    AbbVie
    AstraZeneca
    Bayer
    Biogen
    Boehringer Ingelheim
    Boston Biomedical
    Daiichi Sankyo

    Buy now